Our Difference is the Science
Fueling Our Pipeline
The scientists of Ymmunobio are innovating cancer treatment with novel therapeutic antibodies. Our novel CEACAM1 antibody not only acts as a checkpoint inhibitor but also as an immune agonist, stimulating B- and T-cells to fight cancer.
Our first-in-class YB-800 antibody directly targets various cancers overexpressing New target receptor so that health tissue is not affected.
Our fully humanized anti CEACAM1 antibody targets cell-to-cell communication, in order to promote an increase in efficiency of the immune response to tumor cells.
Our dual action lead asset overcomes resistance by directly co-stimulating immune cells. We were able to demonstrate proof of concept in a syngeneic Hepa 1-6 mouse model.
YB-200 shows tumor reduction effects in immune sensitive and immune resistant Hepa 1-6 models:
Immune resistant Hepa 1-6 Model:
Checkpoint inhibitors show no effect
Immune sensitive Hepa 1-6 Model: Comparison with checkpoint inhibitor
Janicot M et al. 2022, J Immunotherapy of Cancer (Suppl 2) A1436
Along with instigating cell-to-cell communication, the antibody can also act as a checkpoint inhibitor disrupting the interaction of CEACAM1 on tumor and immune cells. The lead indication for YB-200 is Hepatocellular Carcinoma (HCC).
The FDA has granted YB-200 Orphan Drug Designation (ODD) for the treatment of HCC.
Our research into a new target receptor in oncology is focused on its development as a first-in-class ADC (antibody drug conjugate) target in GI cancers. Our fully humanized antibody binds to tumor cells selectively, and healthy tissue is not affected.
The new target receptor was discovered through analyses of a large tumor bank.
ADC development work is currently ongoing.